Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paeoniflorin glucosides adverse effect registry in rheumatic disease and dermatology patients
ChiCTR1800018652Phase 4Recruiting
- Sponsor
- Department of Rheumatology and Immunology
- Start
- Apr 2018
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of total glucosides of paeony in rheumatism, Not applicable (entry is a general category, not a specific disease) and rheumatoid arthritis (RA), sponsored by Department of Rheumatology and Immunology. Primary endpoint: Incidence of adverse reactions during 1 month of medication. Started Apr 2018; status: recruiting.
02
Drugs
total glucosides of paeony
03
Conditions
rheumatismNot applicable (entry is a general category, not a specific disease)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR1800018652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018652.